PMID- 31269839
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20201116
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
VI  - 30
IP  - 4
DP  - 2020 Jul
TI  - Comparative efficacy and safety of immunosuppressive therapies for systemic 
      sclerosis related interstitial lung disease: A Bayesian network analysis.
PG  - 687-695
LID - 10.1080/14397595.2019.1640343 [doi]
AB  - Objectives: Immunosuppressive therapies for the treatment of patients with 
      systemic sclerosis (SSc) and SSc related interstitial lung diseases (SSc-ILD) 
      include cyclophosphamide (CYC), mycophenolate mofetil (MMF), azathioprine (AZA) 
      and methotrexate (MTX). The objectives were to compare and rank these therapies 
      in term of forced vital capacity (FVC) % predicted, diffusing capacity of the 
      lung for carbon monoxide (DLco) % predicted and adverse events (AEs).Methods: We 
      present pooled estimates of mean difference (MD) and odds rates (ORs) with 95% 
      confidence intervals (CIs) among different therapies. We also ranked these agents 
      with surface under the cumulative ranking probability (SUCRA).Results: CYC plus 
      AZA had the highest SUCRA probability (70%) on reducing risk of the deterioration 
      of FVC compared with CYC, observation (OBS), MMF and AZA. While for the 
      prevention of the deterioration of DLco, MMF showed the highest SUCRA probability 
      (76%) compared with others. Moreover, AZA showed the lowest probability (32%) for 
      AEs among active interventions.Conclusions: CYC plus AZA was the preferred 
      immunosuppressive strategies compared to others on preventing the deterioration 
      of FVC. MMF resulted with the highest probability as the best in preventing the 
      deterioration of DLco. Monotherapy of AZA was less pulmonary function benefit but 
      related less AEs.
FAU - Zheng, Ji-Na
AU  - Zheng JN
AUID- ORCID: 0000-0002-0644-1937
AD  - Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Yang, Qiao-Rong
AU  - Yang QR
AD  - Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Zhu, Gui-Qi
AU  - Zhu GQ
AUID- ORCID: 0000-0001-5089-6923
AD  - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
AD  - State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, China.
FAU - Pan, Lin
AU  - Pan L
AD  - Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Xia, Jing-Xian
AU  - Xia JX
AD  - Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Wang, Qiang
AU  - Wang Q
AUID- ORCID: 0000-0002-0466-5013
AD  - Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20190722
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Immunosuppressive Agents)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - HU9DX48N0T (Mycophenolic Acid)
RN  - MRK240IY2L (Azathioprine)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adult
MH  - Azathioprine/adverse effects/therapeutic use
MH  - Bayes Theorem
MH  - Cyclophosphamide/adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*adverse effects/therapeutic use
MH  - Lung Diseases, Interstitial/*drug therapy/etiology
MH  - Male
MH  - Methotrexate/adverse effects/therapeutic use
MH  - Middle Aged
MH  - Mycophenolic Acid/adverse effects/therapeutic use
MH  - Scleroderma, Systemic/complications/*drug therapy
MH  - Treatment Outcome
MH  - Vital Capacity
OTO - NOTNLM
OT  - Immunotherapy
OT  - immunosuppressive therapies
OT  - interstitial lung diseases
OT  - network meta-analysis
OT  - systemic sclerosis
EDAT- 2019/07/05 06:00
MHDA- 2020/11/18 06:00
CRDT- 2019/07/05 06:00
PHST- 2019/07/05 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2019/07/05 06:00 [entrez]
AID - 10.1080/14397595.2019.1640343 [doi]
PST - ppublish
SO  - Mod Rheumatol. 2020 Jul;30(4):687-695. doi: 10.1080/14397595.2019.1640343. Epub 
      2019 Jul 22.